✅ I'm very happy to announce that after 1 year of intense labor ⏱️ our #RECOMMENDATIONS 🧑🎓 for PHYSICAL ACTIVITY & EXERCISE 🏃🏋️⛹️🤸 for persons living with #LUPUS 🦋 are now ONLINE! For FREE, for all 👍
DIRECT DOWNLOAD LINK 📥https://t.co/SdN1DTyCeq
🩺In the management of rheumatoid arthritis, #cardiovascular risk assessment remains a pivotal yet under-discussed aspect. 🧐Are current methodologies for risk calculation being universally applied? Interesting talk by F Cacciapaglia 👏#Rheumatology#ClinicalDebate@CongressoSir
how often do we discontinue #glucocorticoids in patients with rheumatoid #arthritis? Thanks to a predefined tapering schedule we did it in 12 weeks in 30% of patients who starting tofacitinib. The paper has just been published in Sientific Reports
👉https://t.co/T18yeGjm8v
📢📢Discutiamo insieme le basi biologiche e cliniche della sicurezza dei JAK-inibitori! Ti aspettiamo giovedì 19 Gennaio alle ore 15 online‼️
Per iscriversi ➡️https://t.co/LJsZ1apZH0
Still imagining a future where not only a chest HRCT can diagnose RA-ILD but also provide digital biomarkers for prognosis and treatment selection.
Too far? Possibly but radiomics can make it happen💪🏻
Our latest manuscript👇🏻
https://t.co/OKEIVpnslL
Profiling #rheumatoid arthritis patients at higher risk of MACE: cardiovascular history and cardiovascular risk factors matter. Comment on the ORAL Surveillance post hoc analysis, just published in @ARD_BMJ @vincevenerito@garufi_cristina
➡https://t.co/i6C2FoAptQ
Any comment?!?